Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGILE THERAPEUTICS INCAGRX · Entity 87994 | Director | June 06, 2019 | June 07, 2019 |
| Assertio Therapeutics, IncASRT · Entity 149352 | Director | May 09, 2019 | May 09, 2019 |
| C4 Therapeutics, Inc.CCCC · Entity 5503 | Chief Financial Officer | October 06, 2020 | October 07, 2020 |
| Dare Bioscience, Inc.CERU · Entity 7799 | Director | January 03, 2017 | January 05, 2017 |
| Rein Therapeutics, Inc.ALRN · Entity 7071 | Director | June 15, 2022 | June 17, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGILE THERAPEUTICS INC
Report date June 06, 2019 · Filed June 07, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2029-06-05 | Direct | 75,000 |
Reported balance
After 2019-06-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-06 · Grant · Acquired 75,000 · Balance 75,000 F1: The option was granted on June 6, 2019 and vests in full on June 6, 2020, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on June 6, 2019 and vests in full on June 6, 2020, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service.
Assertio Therapeutics, Inc
Report date May 09, 2019 · Filed May 09, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 67,846 |
Reported balance
After 2019-05-09 transaction · row 1
1 source rowRow 1 · 2019-05-09 · Sale · Disposed 12,500 · Balance 67,846 F1: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2019. F2: The price reported is a weighted average sale price. The shares were sold in multiple same-way transactions on May 9, 2019 at prices ranging from $4.50 to $4.90 per share of common stock. If requested by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, the reporting person will provide full information regarding the number of shares of common stock sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2019.
F2: The price reported is a weighted average sale price. The shares were sold in multiple same-way transactions on May 9, 2019 at prices ranging from $4.50 to $4.90 per share of common stock. If requested by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, the reporting person will provide full information regarding the number of shares of common stock sold at each separate price.
C4 Therapeutics, Inc.
Report date October 06, 2020 · Filed October 07, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,263 |
Reported balance
After 2020-10-06 transaction · row 1
1 source rowRow 1 · 2020-10-06 · Purchase · Acquired 5,263 · Balance 5,263 |
Dare Bioscience, Inc.
Report date January 03, 2017 · Filed January 05, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,418 |
Reported balance
After 2017-01-03 transaction · row 1
1 source rowRow 1 · 2017-01-03 · Grant · Acquired 1,948 · Balance 3,418 F1: Consists of shares of common stock issued in lieu of cash retainers for board and committee service in accordance with an election of the reporting person under the company's non-employee director compensation program. The number of shares is equal to the amount of the cash retainers that would otherwise have been payable to the reporting person for the fourth fiscal quarter of 2016 divided by $0.77, the closing price of the company's common stock on the NASDAQ Global Market on January 3, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of shares of common stock issued in lieu of cash retainers for board and committee service in accordance with an election of the reporting person under the company's non-employee director compensation program. The number of shares is equal to the amount of the cash retainers that would otherwise have been payable to the reporting person for the fourth fiscal quarter of 2016 divided by $0.77, the closing price of the company's common stock on the NASDAQ Global Market on January 3, 2017.
Rein Therapeutics, Inc.
Report date June 15, 2022 · Filed June 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.40 · Expires 2032-06-14 | Direct | 54,500 |
Reported balance
After 2022-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-15 · Grant · Acquired 54,500 · Balance 54,500 F1: This option was granted on June 15, 2022. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 15, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 15, 2022. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 15, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Assertio Holdings, Inc.
Report date June 16, 2026 · Filed June 16, 2026
Section 16 reporting ended · disclosed 2026-06-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Other · Disposed 27,936 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 13, 2026, by and among Assertio Holdings, Inc. (the "Issuer"), Zydus Worldwide DMCC ("Parent"), Zara Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser") and Zydus Pharmaceuticals (USA) Inc., pursuant to which Purchaser completed a tender offer (the "Offer") for all outstanding shares of common stock of the Issuer ("Company Common Stock") at a price of $23.50 per share in cash, without interest (the "Offer Price"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"), effective as of June 16, 2026 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right [continues to Footnote 2] F2: [continues from Footnote 1] to receive the Offer Price, less any applicable withholding taxes. F3: Pursuant to the Merger Agreement, each restricted stock unit of the Issuer (each, a "Company RSU") that was outstanding but unvested immediately prior to the Effective Time became fully vested as of immediately prior to the Effective Time and, at the Effective Time, each outstanding Company RSU was cancelled and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the Offer Price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.15 | Direct | 0 |
Reported balance
After 2026-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-16 · Disposition to issuer · Disposed 5,415 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.26 | Direct | 0 |
Reported balance
After 2026-06-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-16 · Disposition to issuer · Disposed 5,415 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 13, 2026, by and among Assertio Holdings, Inc. (the "Issuer"), Zydus Worldwide DMCC ("Parent"), Zara Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser") and Zydus Pharmaceuticals (USA) Inc., pursuant to which Purchaser completed a tender offer (the "Offer") for all outstanding shares of common stock of the Issuer ("Company Common Stock") at a price of $23.50 per share in cash, without interest (the "Offer Price"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"), effective as of June 16, 2026 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right [continues to Footnote 2]
F2: [continues from Footnote 1] to receive the Offer Price, less any applicable withholding taxes.
F3: Pursuant to the Merger Agreement, each restricted stock unit of the Issuer (each, a "Company RSU") that was outstanding but unvested immediately prior to the Effective Time became fully vested as of immediately prior to the Effective Time and, at the Effective Time, each outstanding Company RSU was cancelled and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the Offer Price.
F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 16, 2026 22:38 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,415 | Not disclosed Strike: $9.26 | Not disclosed |
DisclosureSEC source: 0001104659-26-074753 · tm2618077-9_4seq1.xml · derivative · entry 3 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,415 shares Expires not disclosed F4 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof. Read SEC document |
| June 16, 2026 Filed Jun 16, 2026 22:38 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,415 | Not disclosed Strike: $15.15 | Not disclosed |
DisclosureSEC source: 0001104659-26-074753 · tm2618077-9_4seq1.xml · derivative · entry 2 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,415 shares Expires not disclosed F4 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof. Read SEC document |
| June 16, 2026 Filed Jun 16, 2026 22:38 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | OtherCommon Stock | 27,936 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-074753 · tm2618077-9_4seq1.xml · nonDerivative · entry 1 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 13, 2026, by and among Assertio Holdings, Inc. (the "Issuer"), Zydus Worldwide DMCC ("Parent"), Zara Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser") and Zydus Pharmaceuticals (USA) Inc., pursuant to which Purchaser completed a tender offer (the "Offer") for all outstanding shares of common stock of the Issuer ("Company Common Stock") at a price of $23.50 per share in cash, without interest (the "Offer Price"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"), effective as of June 16, 2026 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right [continues to Footnote 2] F2 · shares: [continues from Footnote 1] to receive the Offer Price, less any applicable withholding taxes. F3 · shares: Pursuant to the Merger Agreement, each restricted stock unit of the Issuer (each, a "Company RSU") that was outstanding but unvested immediately prior to the Effective Time became fully vested as of immediately prior to the Effective Time and, at the Effective Time, each outstanding Company RSU was cancelled and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the Offer Price. Read SEC document |
| May 05, 2026 Filed May 6, 2026 22:02 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantCommon Stock | 4,851 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-056413 · tm2613761-4_4seq1.xml · nonDerivative · entry 1 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,936 F1 · shares: Restricted stock units that (1) vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting, and (2) were granted on the date of the Issuer's 2026 Annual Meeting of Stockholders in accordance with the Issuer's Nonemployee Director Compensation & Grant Policy. F2 · balance_after: On December 26, 2025, the Issuer effected a 1-for-15 reverse stock split (the "Reverse Stock Split"). The number of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| May 07, 2025 Filed May 9, 2025 22:01 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantStock Option (right to buy) · Derivative | 81,225 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001104659-25-046867 · tm2514518-4_4seq1.xml · derivative · entry 2 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,225 Underlying: Common Stock · 81,225 shares Expires 2035-05-07 F3 · price: These derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for these derivative securities. F2 · derivative.exercise_date: Stock Options that (1) vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting, and (2) were granted on the date of the Issuer's 2025 Annual Meeting of Stockholders in accordance with the Issuer's Nonemployee Director Compensation & Grant Policy. Read SEC document |
| May 07, 2025 Filed May 9, 2025 22:01 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantCommon Stock | 53,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-046867 · tm2514518-4_4seq1.xml · nonDerivative · entry 1 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 346,280 F1 · shares: Restricted stock units that (1) vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting, and (2) were granted on the date of the Issuer's 2025 Annual Meeting of Stockholders in accordance with the Issuer's Nonemployee Director Compensation & Grant Policy. Read SEC document |
| May 23, 2024 Filed May 29, 2024 00:00 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantStock Option (right to buy) · Derivative | 81,225 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001104659-24-065699 · tm2415689-3_4seq1.xml · derivative · entry 2 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,225 Underlying: Common Stock · 81,225 shares Expires 2034-05-23 F3 · price: These derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for these derivative securities. F2 · derivative.exercise_date: Stock Options that (1) vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting, and (2) were granted on the date of the Issuer's 2024 Annual Meeting of Stockholders in accordance with the Issuer's Nonemployee Director Compensation & Grant Policy. Read SEC document |
| May 23, 2024 Filed May 29, 2024 00:00 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantCommon Stock | 53,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-065699 · tm2415689-3_4seq1.xml · nonDerivative · entry 1 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 292,530 F1 · shares: Restricted stock units that (1) vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting, and (2) were granted on the date of the Issuer's 2024 Annual Meeting of Stockholders in accordance with the Issuer's Nonemployee Director Compensation & Grant Policy. Read SEC document |
| August 14, 2023 Filed Aug 15, 2023 22:00 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | SaleCommon Stock | 22,000 | $3.14 | $69,044.80 |
DisclosureSEC source: 0001104659-23-092060 · tm2322708-4_4seq1.xml · nonDerivative · entry 1 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 238,780 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. F2 · price: The price reported is a weighted average sale price. The shares were sold in multiple same-way transactions on August 14, 2023 at prices ranging from $3.11 to $3.26 per share of common stock. If requested by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, the reporting person will provide full information regarding the number of shares of common stock sold at each separate price. Read SEC document |
| May 10, 2023 Filed May 12, 2023 22:35 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantStock Option (right to buy) · Derivative | 3,821 | $0.00 Strike: $7.55 | $0.00 |
DisclosureSEC source: 0001808665-23-000037 · wf-form4_168393090166231.xml · derivative · entry 2 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,821 Underlying: Common Stock · 3,821 shares Expires 2033-05-10 F3 · price: These derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for these derivative securities. F2 · derivative.exercise_date: Stock Options that vest in full on the first anniversary of the grant date and which were granted on the date of the Issuer's 2023 Annual Meeting of Stockholders in accordance with the Issuer's Nonemployee Director Compensation & Grant Policy. Read SEC document |
| May 10, 2023 Filed May 12, 2023 22:35 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantCommon Stock | 31,194 | $0.00 | $0.00 |
DisclosureSEC source: 0001808665-23-000037 · wf-form4_168393090166231.xml · nonDerivative · entry 1 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,780 F1 · shares: Restricted stock units that vest in full on the first anniversary of the grant date and which were granted on the date of the Issuer's 2023 Annual Meeting of Stockholders in accordance with the Issuer's Nonemployee Director Compensation & Grant Policy. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 21:18 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 54,500 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0000899243-22-023146 · doc4.xml · derivative · entry 1 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,500 Underlying: Common Stock · 54,500 shares Expires 2032-06-14 F1 · derivative.exercise_date: This option was granted on June 15, 2022. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 15, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders. Read SEC document |
| May 12, 2022 Filed May 16, 2022 23:16 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | SaleCommon Stock | 22,322 | $2.35 | $52,487.95 |
DisclosureSEC source: 0001808665-22-000036 · wf-form4_165274298643886.xml · nonDerivative · entry 1 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,586 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2021 to cover taxes upon the May 11, 2022 vesting of restricted stock units. F2 · price: The price reported is a weighted average sale price. The shares were sold in multiple same-way transactions on May 12, 2022 at prices ranging from $2.195 to $2.53 per share of common stock. If requested by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, the reporting person will provide full information regarding the number of shares of common stock sold at each separate price. Read SEC document |
| May 04, 2022 Filed May 7, 2022 00:14 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantCommon Stock | 86,286 | $0.00 | $0.00 |
DisclosureSEC source: 0001237262-22-000001 · wf-form4_165188246286133.xml · nonDerivative · entry 1 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,908 F1 · shares: Restricted stock units that vest in full on the first anniversary of the grant date and which were granted on the date of the Issuer's 2022 Annual Meeting of Stockholders in accordance with the Issuer's Nonemployee Director Compensation & Grant Policy. F2 · balance_after: On May 18, 2021 the Issuer effected a 1-for-4 reverse stock split (the "Reverse Stock Split"). The number of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 23:51 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 96,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0000899243-21-024526 · doc4.xml · derivative · entry 1 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,000 Underlying: Common Stock · 96,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: This option was granted on June 15, 2021. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 15, 2022 or (ii) the date of the Issuer's 2022 Annual Meeting of Stockholders. Read SEC document |
| May 11, 2021 Filed May 13, 2021 21:26 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantCommon Stock | 357,143 | $0.00 | $0.00 |
DisclosureSEC source: 0001808665-21-000045 · wf-form4_162094115693414.xml · nonDerivative · entry 1 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 662,489 F1 · shares: Restricted stock units that vest in full on the first anniversary of the grant date. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 01:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | PurchaseCommon Stock | 5,263 | $19.00 | $99,997.00 |
DisclosureSEC source: 0000899243-20-027698 · doc4.xml · nonDerivative · entry 1 MCKEE WILLIAM · CIK 0001237262 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,263 Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 20:32 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0000899243-20-017084 · doc4.xml · derivative · entry 1 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2030-06-16 F1 · derivative.exercise_date: This option was granted on June 17, 2020. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 17, 2021 or (ii) the date of the Issuer's 2021 Annual Meeting of Stockholders. Read SEC document |
| May 19, 2020 Filed May 22, 2020 01:04 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantCommon Stock | 237,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001808665-20-000009 · wf-form4_159010946122219.xml · nonDerivative · entry 1 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,346 F1 · date: As a result of a holding company reorganization effective May 19, 2020, Assertio Holdings, Inc., is the successor issuer to Assertio Therapeutics, Inc., pursuant to 12g-3(a) of the Exchange Act. F2 · shares: Restricted stock units that vest in full on the first anniversary of the grant date. Read SEC document |
| June 19, 2019 Filed Jun 24, 2019 21:17 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0000899243-19-017965 · doc4.xml · derivative · entry 1 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: This option was granted on June 19, 2019. The shares underlying the option are scheduled to vest in equal annual installments over three years from June 19, 2019. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 16:32 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001104659-19-034557 · a4.xml · derivative · entry 1 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-06-05 F1 · derivative.exercise_date: The option was granted on June 6, 2019 and vests in full on June 6, 2020, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document |
| May 09, 2019 Filed May 9, 2019 22:26 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | SaleCommon Stock | 12,500 | $4.70 | $58,698.75 |
DisclosureSEC source: 0001005201-19-000080 · wf-form4_155744076923920.xml · nonDerivative · entry 1 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,846 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2019. F2 · price: The price reported is a weighted average sale price. The shares were sold in multiple same-way transactions on May 9, 2019 at prices ranging from $4.50 to $4.90 per share of common stock. If requested by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, the reporting person will provide full information regarding the number of shares of common stock sold at each separate price. Read SEC document |
| May 08, 2019 Filed May 9, 2019 15:30 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | Exercise / conversionRestricted Stock Units · Derivative | 31,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001005201-19-000076 · wf-form4_155741579027885.xml · derivative · entry 3 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,250 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock. F3 · price: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. Read SEC document |
| May 08, 2019 Filed May 9, 2019 15:30 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | Exercise / conversionCommon Stock | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001005201-19-000076 · wf-form4_155741579027885.xml · nonDerivative · entry 2 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2019 Filed May 9, 2019 15:30 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | GrantCommon Stock | 39,584 | $0.00 | $0.00 |
DisclosureSEC source: 0001005201-19-000076 · wf-form4_155741579027885.xml · nonDerivative · entry 1 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,096 F1 · shares: Restricted stock units that vest in full on the first anniversary of the grant date. Read SEC document |
| December 14, 2018 Filed Dec 17, 2018 15:53 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | SaleCommon Stock | 10,000 | $4.07 | $40,693.00 |
DisclosureSEC source: 0001005201-18-000027 · wf-form4_154506197647847.xml · nonDerivative · entry 1 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,512 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2018. F2 · price: The price reported is a weighted average sale price. The shares were sold in multiple same-way transactions on December 14, 2018 at prices ranging from $3.99 to $4.16 per share of common stock. If requested by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, the reporting person will provide full information regarding the number of shares of common stock sold at each separate price. Read SEC document |
| June 08, 2018 Filed Jun 8, 2018 17:03 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Exercise / conversionRestricted Stock Units · Derivative | 17,949 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-039223 · a4.xml · derivative · entry 3 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,949 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On June 8, 2017, the Reporting Person was granted 17,949 restricted stock units, vesting in full on June 8, 2018, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attended at least 75% of the board meetings held during the year of board service. F3 · derivative.expiration_date: On June 8, 2017, the Reporting Person was granted 17,949 restricted stock units, vesting in full on June 8, 2018, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attended at least 75% of the board meetings held during the year of board service. Read SEC document |
| June 08, 2018 Filed Jun 8, 2018 17:03 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Exercise / conversionCommon Stock | 17,949 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-039223 · a4.xml · nonDerivative · entry 1 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 17:03 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001104659-18-039223 · a4.xml · derivative · entry 2 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-06-06 F2 · derivative.exercise_date: The option was granted on June 7, 2018 and vests in full on June 7, 2019, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document |
| May 15, 2018 Filed Feb 14, 2019 21:19 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | Exercise / conversionRestricted Stock Units · Derivative | 19,512 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001005201-19-000020 · wf-form5_155017916193096.xml · derivative · entry 2 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,512 shares Expires 2018-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock. F2 · price: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. Read SEC document |
| May 15, 2018 Filed Feb 14, 2019 21:19 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | Exercise / conversionCommon Stock | 19,512 | $0.00 | $0.00 |
DisclosureSEC source: 0001005201-19-000020 · wf-form5_155017916193096.xml · nonDerivative · entry 1 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2018 Filed May 11, 2018 00:07 UTC | Assertio Therapeutics, Inc DEPO · Entity 149352 | GrantRestricted Stock Units · Derivative | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-006587 · edgar.xml · derivative · entry 1 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,250 Underlying: Common Stock · 31,250 shares Expires not disclosed F1 · security: Grant of restricted stock unit awards pursuant to the Company's Non-Employee Director Compensation and Grant Policy. F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F3 · derivative.exercise_date: These restricted stock units are scheduled to vest on May 08, 2019, assuming continued service through the applicable vesting date. F3 · derivative.expiration_date: These restricted stock units are scheduled to vest on May 08, 2019, assuming continued service through the applicable vesting date. Read SEC document |
| August 15, 2017 Filed Aug 16, 2017 22:41 UTC | Assertio Therapeutics, Inc DEPO · Entity 149352 | GrantRestricted Stock Units · Derivative | 19,512 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-011572 · edgar.xml · derivative · entry 1 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,512 Underlying: Common Stock · 19,512 shares Expires not disclosed F1 · security: Grant of restricted stock unit awards pursuant to the Company's Non-Employee Director Compensation and Grant Policy. F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F3 · derivative.exercise_date: These restricted stock units are scheduled to vest on May 15, 2018, assuming continued service through the applicable vesting date. F3 · derivative.expiration_date: These restricted stock units are scheduled to vest on May 15, 2018, assuming continued service through the applicable vesting date. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 17:04 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantRestricted Stock Units · Derivative | 17,949 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-038465 · a4.xml · derivative · entry 2 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,949 Underlying: Common Stock · 17,949 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: The restricted stock units were granted on June 8, 2017 and vest in full on June 8, 2018, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. F3 · derivative.expiration_date: The restricted stock units were granted on June 8, 2017 and vest in full on June 8, 2018, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 17:04 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001104659-17-038465 · a4.xml · derivative · entry 1 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2027-06-07 F1 · derivative.exercise_date: The option was granted on June 8, 2017 and vests in full on June 8, 2018, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document |
| March 28, 2017 Filed Mar 30, 2017 20:22 UTC | Assertio Therapeutics, Inc DEPO · Entity 149352 | GrantStock Option · Derivative | 29,268 | $0.00 Strike: $14.23 | $0.00 |
DisclosureSEC source: 0001179110-17-005249 · edgar.xml · derivative · entry 1 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,268 Underlying: Common Stock · 29,268 shares Expires 2027-03-28 F1 · derivative.exercise_date: These stock options are exercisable in 36 equal monthly installments. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:22 UTC | Dare Bioscience, Inc. CERU · Entity 7799 | GrantCommon Stock | 1,948 | $0.77 | $1,499.96 |
DisclosureSEC source: 0001209191-17-002074 · doc4.xml · nonDerivative · entry 1 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,418 F1 · price: Consists of shares of common stock issued in lieu of cash retainers for board and committee service in accordance with an election of the reporting person under the company's non-employee director compensation program. The number of shares is equal to the amount of the cash retainers that would otherwise have been payable to the reporting person for the fourth fiscal quarter of 2016 divided by $0.77, the closing price of the company's common stock on the NASDAQ Global Market on January 3, 2017. Read SEC document |
| October 03, 2016 Filed Oct 20, 2016 22:59 UTC | Dare Bioscience, Inc. CERU · Entity 7799 | GrantCommon Stock | 1,470 | $1.02 | $1,499.40 |
DisclosureSEC source: 0001209191-16-146521 · doc4.xml · nonDerivative · entry 1 MCKEE WILLIAM · CIK 0001237262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,470 F1 · shares: Consists of shares of common stock issued in lieu of cash retainers for board and committee service in accordance with an election of the reporting person under the company's non-employee director compensation program. The number of shares is equal to the amount of the cash retainers that would otherwise have been payable to the reporting person for the third fiscal quarter of 2016 divided by $1.02, the closing price of the company's common stock on the NASDAQ Global Market on October 3, 2016. F1 · price: Consists of shares of common stock issued in lieu of cash retainers for board and committee service in accordance with an election of the reporting person under the company's non-employee director compensation program. The number of shares is equal to the amount of the cash retainers that would otherwise have been payable to the reporting person for the third fiscal quarter of 2016 divided by $1.02, the closing price of the company's common stock on the NASDAQ Global Market on October 3, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.